Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume -, Issue -, Pages 1-13
Publisher
Informa UK Limited
Online
2021-05-22
DOI
10.1080/21645515.2021.1888621
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Designing ecologically optimized pneumococcal vaccines using population genomics
- (2020) Caroline Colijn et al. Nature Microbiology
- Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
- (2020) Donald Hurley et al. CLINICAL INFECTIOUS DISEASES
- Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe
- (2019) C. Bonnave et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Early Impact of 13-valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease among Adults with and without Underlying Medical Conditions—United States
- (2019) Sana S Ahmed et al. CLINICAL INFECTIOUS DISEASES
- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
- (2019) Almea Matanock et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age
- (2018) Susan J. Ermlich et al. VACCINE
- Prevention of Pneumococcal Infections in Adults using Conjugate Vaccines: No Easy Answers
- (2018) Daniel M Weinberger et al. CLINICAL INFECTIOUS DISEASES
- Decision-making for PCV in adults
- (2018) John M. McLaughlin et al. Human Vaccines & Immunotherapeutics
- Development of pneumococcal vaccines over the last 10 years
- (2017) Nicola Principi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis
- (2017) Anthony Lopez et al. JOURNAL OF AUTOIMMUNITY
- Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with Streptococcus pneumoniae infections
- (2017) Jacob B. Morton et al. VACCINE
- Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
- (2015) Pauline A Waight et al. LANCET INFECTIOUS DISEASES
- Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
- (2015) Marc J.M. Bonten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant
- (2015) Daniel M. Musher et al. Human Vaccines & Immunotherapeutics
- Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
- (2015) Masanari Shiramoto et al. Human Vaccines & Immunotherapeutics
- Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
- (2015) Miwako Kobayashi et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Rethinking Risk for Pneumococcal Disease in Adults: The Role of Risk Stacking
- (2015) Stephen I. Pelton et al. Open Forum Infectious Diseases
- Early Impact of 13-Valent Pneumococcal Conjugate Vaccine on Community-Acquired Pneumonia in Children
- (2014) F. Angoulvant et al. CLINICAL INFECTIOUS DISEASES
- Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age
- (2014) Richard N. Greenberg et al. VACCINE
- Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults
- (2014) Christine Juergens et al. Human Vaccines & Immunotherapeutics
- How Effective is Vaccination in Preventing Pneumococcal Disease?
- (2013) Daniel M. Musher INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults
- (2013) Kenneth J. Smith et al. VACCINE
- Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
- (2013) Lisa A. Jackson et al. VACCINE
- Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Alaska Native Adults 55–70 Years of Age
- (2009) Karen M. Miernyk et al. CLINICAL INFECTIOUS DISEASES
- The Immunogenicity of 7‐Valent Pneumococcal Conjugate Vaccine versus 23‐Valent Polysaccharide Vaccine in Adults Aged 50–80 Years
- (2009) David Goldblatt et al. CLINICAL INFECTIOUS DISEASES
- Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine
- (2009) Tamara Pilishvili et al. JOURNAL OF INFECTIOUS DISEASES
- Comparison of Pneumococcal Conjugate Polysaccharide and Free Polysaccharide Vaccines in Elderly Adults: Conjugate Vaccine Elicits Improved Antibacterial Immune Responses and Immunological Memory
- (2008) Andrés de Roux et al. CLINICAL INFECTIOUS DISEASES
- Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency
- (2008) Jeremy G. Schenkein et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now